Friday 6 November 2026
Export DGX’s income statement to Excel — free account
Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.
- Revenue
- +9.98%
- EPS
- +29.4%
- Free cash flow
- +6.21%
- Total debt
- −2.20%
Quarter to September 2026, against a year earlier
255.57
0.83
+0.33%
Follow DGX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 8 | 7 |
| 14.10% | 13.95% | 14.03% | 14.76% | ||
| 6.10% | 6.28% | 6.43% | 6.73% | ||
ROIC |
7.81% | 7.78% | 7.94% | 8.48% | |
Return on Tangible Assets |
42.90% | 39.57% | 32.31% | 31.62% | |
Average Days of Receivables |
46.57 | 51.36 | 52.60 | 52.77 | |
Free Cash Flow per Share |
12.24 | 12.05 | 12.15 | 12.50 | |
Free Cash Flow |
1,359.00 | 1,326.00 | 1,349.00 | 1,375.00 | |
Capital Expenditures |
(527.00) | (524.00) | (554.00) | (576.00) | |
| Other line items | |||||
Cash ROIC |
10.22% | 9.67% | 9.58% | 9.62% | |
Accounts Receivable Turnover |
8.14 | 7.54 | 7.49 | 7.48 | |
Accounts Payable Turnover |
4.92 | 5.45 | 5.25 | 5.11 | |
Inventory Turnover |
39.10 | 36.40 | 36.82 | 39.21 | |
Average Days of Payables |
79.24 | 72.67 | 75.44 | 75.72 | |
Days of Inventory on Hand |
9.36 | 10.90 | 11.00 | 10.05 | |
Tax Rate |
(0.24) | (0.24) | (0.23) | (0.23) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
17.83% | 17.69% | 17.63% | 17.40% | |
Share Based Compensation of Revenue |
0.80% | 0.76% | 0.76% | 0.74% | |
Interest Coverage |
5.89 | 6.19 | 6.37 | 6.86 | |
Operating CF/Net income |
1.91 | 1.81 | 1.80 | 1.73 | |
Depreciation/Fixed assets |
0.26 | 0.26 | 0.26 | 0.26 | |
Capex/Depreciation |
(0.92) | (0.91) | (0.96) | (0.98) | |
Revenue per Share |
99.41 | 102.53 | 104.14 | 107.65 | |
Operating CF per Share |
16.99 | 16.82 | 17.14 | 17.74 | |
Capex per Share |
(4.75) | (4.76) | (4.99) | (5.24) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 2 Nov 2026